Jacob Rosenberg

Jacob has more than 22 years of experience in clinical research and development operations. Before joining ImmPACT, Jacob was Vice President, Clinical Operations at Turnstone Biologics where he was responsible for the first-in-human trial of an autologous Tumor Infiltrating Lymphocytes, or TILs, for solid tumors.  Prior to that, he was Senior Director of Clinical Operations at Allogene Therapeutics where Jacob was responsible for multiple First In Human allogenic CAR-T therapies in Multiple Myeloma and Renal Cell Carcinoma.  Earlier in his career, Jacob worked at Atara Biotherapeutics, Nektar Therapeutics and Amgen, mostly in hematology and oncology clinical trials.  He received his MBA from Keller Graduate School of Management of Devry University, and Bachelor of Science degree in Biology from University of North Florida.